GUMDROP : Randomized Phase II Trial of Docetaxel with or without PSA-TRICOM Vaccine in Patients with Castrate-Resistant Metastatic Prostate Cancer (E1809)

Created by Channing Paller, last modified on Apr 14, 2012

Description:

This trial measures the effect of docetaxel (chemotherapy) with or without the vacine PSA-TRICOM, on overall survival of castrate-resistant prostate cancer patients who have confirmed metastases; progressive disease while on androgen deprivation therapy; rising PSA (2 values at 1 week apart and each value = 2.0 ng/mL); NO prior anti-cancer vaccine; prior chemotherapy (if any) < 6 months prior to this trial; NO splenectomy or certain allergies.

Link:

http://clinicaltrials.gov/ct2/show/NCT01145508

Site:

Johns Hopkins Hospital

Principal Investigator:

Charles Drake, M.D.